Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Gevokizumab Treatment for Active Scleritis By IL-1 Inhibition (GATSBY)

NCT01835132 is registered in ClinicalTrials.gov with National Eye Institute (NEI) as lead sponsor.

NCT NCT01835132
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01835132 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Gevokizumab Treatment for Active Scleritis By IL-1 Inhibition (GATSBY)
Lead sponsor
National Eye Institute (NEI)
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2013
Completion date
February 29, 2016
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

scleritis